Corin in cardiovascular diseases and stroke

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-04-30 DOI:10.1016/j.cca.2025.120343

Yue Gong , Yichang Zhao , Yang Li, Qianqian Wang, Chunkai Li, Keyi Song, Jinqiu Liu, Feifei Chen

引用次数: 0

Abstract

Corin is a type II transmembrane serine protease highly expressed in the heart. It plays a critical role in regulating fluid balance and improving cardiac function by converting pro-atrial natriuretic peptide into mature atrial natriuretic peptide. CORIN variants have been identified in patients with hypertension, heart failure, atrial fibrillation, and stroke. In vivo and in vitro, corin deficiency increases blood pressure and impairs cardiac function. Circulating soluble corin appears to have potential as a stable and specific biomarker for the risk prediction and prognostic assessment of cardiovascular diseases (CVDs) and stroke. In this review, we summarize the current knowledge on corin physiology and circulating corin and discuss cardiac corin expression and function in CVDs. In the future, corin-related therapeutic approaches to increase corin activity and raise corin levels may offer new opportunities to treat CVDs.

查看原文本刊更多论文

可用于心血管疾病和中风

Corin是一种在心脏高度表达的II型跨膜丝氨酸蛋白酶。它通过将前房利钠肽转化为成熟房利钠肽，在调节体液平衡和改善心功能中起关键作用。在高血压、心力衰竭、心房颤动和中风患者中发现了CORIN变异。体内和体外，corin缺乏会增加血压，损害心脏功能。循环可溶性科林似乎有潜力作为一种稳定的特异性生物标志物，用于心血管疾病（cvd）和中风的风险预测和预后评估。在本文中，我们综述了目前关于corin生理学和循环corin的知识，并讨论了心脏corin在心血管疾病中的表达和功能。在未来，增加蛋白活性和提高蛋白水平的蛋白相关治疗方法可能为心血管疾病的治疗提供新的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.